Amgen (AMGN) Offering Possible 21.65% Return Over the Next 17 Calendar Days

This post was originally published on this site

Amgen’s most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $227.50 short call and a strike $232.50 long call offers a potential 21.65% return on risk over the next 17 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $227.50 by expiration. The full premium credit of $0.89 would be kept by the premium seller. The risk of $4.11 would be incurred if the stock rose above the $232.50 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.

The RSI indicator is at 36.24 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Amgen

Amgen’s Repatha Improves Plaque Stability In Heart Patients
Fri, 27 Aug 2021 16:11:16 +0000
Amgen Inc (NASDAQ: AMGN) has announced positive data from the HUYGENS Phase 3 study assessing if Repatha (evolocumab) could increase the thickness of the fibrous caps to improve a feature of plaque stability. The data were presented at the oral presentation at ESC Congress 2021. Repatha, in addition to optimized statin therapy, in comparison with optimized statin therapy alone, significantly improved features of plaque stability in patients with coronary artery disease (CAD). The study met its p

New Data At ESC Congress 2021 Shows Repatha® (evolocumab) Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome (ACS)
Fri, 27 Aug 2021 08:30:00 +0000
Amgen (NASDAQ:AMGN) today announced positive data from the HUYGENS Phase 3 study showing that Repatha® (evolocumab) in addition to optimized statin therapy, in comparison with optimized statin therapy alone, significantly improved features of plaque stability in patients with coronary artery disease (CAD). These data are being presented during an oral presentation at ESC Congress 2021, organized by the European Society of Cardiology, Aug. 27-30.

Amgen Joins Growing List of Companies Requiring Employees Get Vaccinated
Thu, 19 Aug 2021 19:56:00 +0000
The biotech told its workers in the U.S. and Puerto Rico that they must be fully vaccinated by Nov. 1. The mandate, however, does make exceptions.

How Are Biotech ETFs Reacting to These Q2 Earnings Releases?
Thu, 12 Aug 2021 19:00:07 +0000
Let’s take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Four Days Left To Buy Amgen Inc. (NASDAQ:AMGN) Before The Ex-Dividend Date
Wed, 11 Aug 2021 11:55:58 +0000
Amgen Inc. ( NASDAQ:AMGN ) stock is about to trade ex-dividend in four days. The ex-dividend date occurs one day before…

Be Sociable, Share!

Related Posts